SG149701A1 - Methods of treating microbial infections in humans and animals - Google Patents

Methods of treating microbial infections in humans and animals

Info

Publication number
SG149701A1
SG149701A1 SG200703939-9A SG2007039399A SG149701A1 SG 149701 A1 SG149701 A1 SG 149701A1 SG 2007039399 A SG2007039399 A SG 2007039399A SG 149701 A1 SG149701 A1 SG 149701A1
Authority
SG
Singapore
Prior art keywords
humans
animals
methods
microbial infections
treating microbial
Prior art date
Application number
SG200703939-9A
Other languages
English (en)
Inventor
Craig A Townsend
James D Dick
Nicole M Parrish
Minerva A Hughes
Original Assignee
Fasgen Llc
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fasgen Llc, Univ Johns Hopkins filed Critical Fasgen Llc
Publication of SG149701A1 publication Critical patent/SG149701A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SG200703939-9A 2002-07-09 2003-07-09 Methods of treating microbial infections in humans and animals SG149701A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39457302P 2002-07-09 2002-07-09

Publications (1)

Publication Number Publication Date
SG149701A1 true SG149701A1 (en) 2009-02-27

Family

ID=30115736

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200703939-9A SG149701A1 (en) 2002-07-09 2003-07-09 Methods of treating microbial infections in humans and animals

Country Status (14)

Country Link
US (1) US20060135568A1 (zh)
EP (1) EP1539147A4 (zh)
JP (1) JP4493494B2 (zh)
KR (1) KR20050047519A (zh)
CN (2) CN1671384A (zh)
AU (1) AU2003248896B2 (zh)
BR (1) BRPI0312654A2 (zh)
CA (1) CA2491573A1 (zh)
EA (1) EA200500177A1 (zh)
IL (1) IL166122A0 (zh)
MX (1) MXPA05000361A (zh)
SG (1) SG149701A1 (zh)
WO (1) WO2004004712A1 (zh)
ZA (1) ZA200500166B (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7649012B2 (en) * 2002-07-09 2010-01-19 Fasgen, Inc. Compounds, pharmaceutical compositions containing same, and methods of use for same
US8653258B2 (en) 2007-06-08 2014-02-18 Georgia State University Research Foundation, Inc. Compositions for regulating or modulating quorum sensing in bacteria, methods of using the compounds, and methods of regulating or modulating quorum sensing in bacteria

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0803577A2 (en) * 1996-04-26 1997-10-29 Toyo Ink Manufacturing Co., Ltd. Method for detecting and/or determining ATP from microorganism cells in a sample
WO2000046347A1 (en) * 1999-02-05 2000-08-10 University Of Texas Genetic and epigenetic regulation of abc transporters and ect0-phosphatases for the modulation of drug resistance
WO2000052144A1 (en) * 1999-03-03 2000-09-08 Board Of Regents, The University Of Texas System Genetic and epigenetic manipulation of abc transporters and ecto-phosphatases for the conference of drug resistance and for the loss of drug resistance in biological systems and methods for the detection of ecto-phosphatase inhibitors
US6392012B1 (en) * 1998-12-23 2002-05-21 Advanced Medicine, Inc. Glycopeptide derivatives and pharmaceutical compositions containing the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2101223A1 (en) * 1970-08-04 1972-03-31 Nasa Bacteria determination in urine - by bioluminescence reaction of bacterial atp
HN2000000051A (es) * 1999-05-19 2001-02-02 Pfizer Prod Inc Derivados heterociclicos utiles como agentes anticancerosos
US6376682B1 (en) * 2000-02-01 2002-04-23 Takama System, Ltd. Compound with α-glucosidase inhibiting action and method for producing the same
US6248790B1 (en) * 2000-06-29 2001-06-19 Parker Hughes Institute Treatment of inflammation with 2,4,6-trihydroxy-alpha-rho-methoxyphenylacetophenone, or its pharmaceutically acceptable derivatives
CN101633650A (zh) * 2002-07-01 2010-01-27 法斯根有限责任公司 新化合物、包含该化合物的药物组合物及该化合物的应用方法
US7649012B2 (en) * 2002-07-09 2010-01-19 Fasgen, Inc. Compounds, pharmaceutical compositions containing same, and methods of use for same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0803577A2 (en) * 1996-04-26 1997-10-29 Toyo Ink Manufacturing Co., Ltd. Method for detecting and/or determining ATP from microorganism cells in a sample
US6392012B1 (en) * 1998-12-23 2002-05-21 Advanced Medicine, Inc. Glycopeptide derivatives and pharmaceutical compositions containing the same
WO2000046347A1 (en) * 1999-02-05 2000-08-10 University Of Texas Genetic and epigenetic regulation of abc transporters and ect0-phosphatases for the modulation of drug resistance
WO2000052144A1 (en) * 1999-03-03 2000-09-08 Board Of Regents, The University Of Texas System Genetic and epigenetic manipulation of abc transporters and ecto-phosphatases for the conference of drug resistance and for the loss of drug resistance in biological systems and methods for the detection of ecto-phosphatase inhibitors

Also Published As

Publication number Publication date
AU2003248896B2 (en) 2010-04-22
KR20050047519A (ko) 2005-05-20
EP1539147A4 (en) 2007-04-25
MXPA05000361A (es) 2005-09-20
CN101721412A (zh) 2010-06-09
AU2003248896A1 (en) 2004-01-23
EA200500177A1 (ru) 2005-12-29
IL166122A0 (en) 2006-01-15
BRPI0312654A2 (pt) 2017-05-02
JP2005533834A (ja) 2005-11-10
ZA200500166B (en) 2007-08-29
JP4493494B2 (ja) 2010-06-30
CA2491573A1 (en) 2004-01-15
US20060135568A1 (en) 2006-06-22
WO2004004712A1 (en) 2004-01-15
CN1671384A (zh) 2005-09-21
EP1539147A1 (en) 2005-06-15

Similar Documents

Publication Publication Date Title
BRPI0608690B8 (pt) uso de uma composição antimicrobiana
CO4700489A1 (es) Un articulo absorbente para inhibir el crecimiento de bacterias dentro del mismo
ECSP105739A (es) Anticuerpos de neutralización contra gdf-8
ATE381336T1 (de) Verwendung von a2a adenosin rezeptor agonisten und anti-pathogene mittel enthaltenden kombinationen zur behandlung von entzündungskrankheiten
WO2003106629A3 (en) TREATMENT OF VITAMIN D INFLUENCED DISEASES
DE69528039T2 (de) Inhibitoren der fettsäuresynthese als antimikrobielle mittel
DE69532921D1 (de) Angesäuertes nitrit zur verwendung als antimikrobielles mittel
WO2008073670A3 (en) Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor
BR0207585A (pt) Método para melhorar o desempenho de crescimento de um animal, composição promotora do crescimento, e, construção para a liberação in vivo de uma quantidade eficaz de citocina
MY158100A (en) 6,9-disubstituted purine derivatives and their use for treating skin
IS2405B (is) Notkun dextransúlfats til að meðhöndla skyndilegtblóðmiðlað bólguviðbragð (IBMIR)
HRP20090583T1 (hr) Novi laktobacil, pripravak laktobacila koji se aktivira u živom organizmu, te preventivno ili terapijsko sredstvo protiv infekcija kod živog organizma
ATE461928T1 (de) Antibakterielle wirkstoffe
CA2388939A1 (en) Therapeutic treatments for blood cell deficiencies
NO20040354L (no) Fremgangsmater og sammensetninger for kontroll av koksidose
EA200401111A1 (ru) Биполярные соли транс-каротиноидов и их применение
DK1675603T3 (da) Anvendelse af probiotiske bakterier i behandling af infektion
BRPI0413413A (pt) feniloxazolidinonas de piperidino substituìdo tendo atividade antimicrobiana com eficácia in vivo melhorada
SG149701A1 (en) Methods of treating microbial infections in humans and animals
PT1140113E (pt) Utilizacao de bisfosfonatos para profilaxia e tratamento de processos infecciosos
WO2005042699A3 (en) Modified polypeptides with therapeutic activity and methods of use
BR0309257A (pt) Aparelho e método para entrega de bactérias no trato vaginal
SE9903611D0 (sv) Novel compounds III
WO2003103699A8 (en) USE OF RAMOPLANIN TO TREAT DISORDERS ASSOCIATED WITH THE TAKING OF ANTIBIOTICS
EP1503781A4 (en) TREATMENT OF WEIGHT LOSS